Bayer has addressed its need for a capital infusion under a deal to secure 3 billion euros ($3.4 billion) in equity from New York City asset manager Apollo, surrendering a minority, non-controlling stake in its newly established long-acting reversible contraceptives business.
Source: FiercePharma
